Apollomics Inc.APLMEarnings & Financial Report
Nasdaq
Apollomics Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative oncology therapies including targeted small molecule drugs and immuno-oncology treatments. It operates globally, prioritizing unmet medical needs in oncology care segments across Asia and other key regions.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Hung-Wen Chen | 12.27% | 13.3M | — | 2024-05-20 |
| Maxpro Investment Co., Ltd | 9.70% | 10.6M | ▲ +0.06pp | 2024-05-30 |
| S.S. | 8.66% | 7.8M | — | 2024-02-27 |
| Guo-Liang Yu | 8.30% | 7.7M | — | 2023-10-10 |
| OrbiMed Advisors LLC | 0.05% | 50.0K | ▼ -7.85pp | 2024-08-15 |